Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial

The seventh IND clearance will expand use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-7 clinical trial targeting a large patient demographic KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE,…

Click here to view original post